[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section includes critical disclaimers from management, the report's structural overview, a list of reference documents, and definitions of key terms and entities [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) Management assures report accuracy, declares no dividends or capital transfers, and outlines key risks such as international trade, R&D, and goodwill impairment - The company's board of directors, supervisory board, and senior management guarantee the **truthfulness, accuracy, and completeness** of the semi-annual report, free from false records, misleading statements, or major omissions, and assume individual and joint legal responsibility[4](index=4&type=chunk) - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) - No exceptionally significant risks substantially impacting the company's operations occurred during the reporting period, but detailed discussions cover **international trade risks, R&D underperformance risks, goodwill impairment risks, exchange rate fluctuation risks, international operation risks, and safety and environmental protection risks**[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=%E7%9B%AE%E5%BD%95) This section lists the report's nine main chapters and their starting page numbers, providing an overall structural overview for investors - The report comprises **nine main chapters**, covering important notices, company profile, management discussion and analysis, corporate governance, significant events, share changes, bond information, financial reports, and other submitted data[7](index=7&type=chunk) [List of Reference Documents](index=4&type=section&id=%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) This section lists all publicly disclosed company documents, original announcements, financial statements, and the original semi-annual report text as reference materials for the reporting period - Reference documents include signed and sealed financial statements, all publicly disclosed original company documents and announcements, the original semi-annual report text signed by the legal representative, and other reference materials[9](index=9&type=chunk) [Definitions](index=5&type=section&id=%E9%87%8A%E4%B9%89) This section defines common terms, the company and its main subsidiaries, R&D products (e.g., F-627, F-652), and relevant regulatory bodies (e.g., NMPA, FDA, EMA) to ensure clear understanding of the report content - The report defines abbreviations for the **Company, Yifan Pharmaceutical, and its main subsidiaries** (e.g., Yifan Bio, Hefei Yifan, Yiyi Bio)[10](index=10&type=chunk)[11](index=11&type=chunk) - **F-627** refers to Epegfilgrastim Injection (Yilishu®/Ryzneuta®), and **F-652** refers to Recombinant Human Interleukin-22-Fc Fusion Protein, both being self-developed R&D products of the company[11](index=11&type=chunk) - **NMPA, FDA, and EMA** refer to the National Medical Products Administration, the U.S. Food and Drug Administration, and the European Medicines Agency, respectively[11](index=11&type=chunk) [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information and presents key financial data and performance indicators for the reporting period [Company Profile](index=7&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Yifan Pharmaceutical Co., Ltd. (stock code: 002019) is listed on the Shenzhen Stock Exchange, with Cheng Xianfeng as its legal representative, and contact information remained unchanged during the reporting period Company Basic Information | Metric | Content | | :--- | :--- | | Stock Abbreviation | Yifan Pharmaceutical | | Stock Code | 002019 | | Listing Exchange | Shenzhen Stock Exchange | | Chinese Name | Yifan Pharmaceutical Co., Ltd. | | Legal Representative | Cheng Xianfeng | - The company's registered address, office address, website, email, and information disclosure locations remained unchanged during the reporting period, as detailed in the 2024 annual report[15](index=15&type=chunk)[16](index=16&type=chunk) [Key Accounting Data and Financial Indicators](index=8&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In H1 2025, operating revenue slightly increased by 0.11% YoY, net profit attributable to shareholders grew by 19.91%, and non-recurring net profit increased by 32.21%, driven by higher innovative drug revenue and increased foreign exchange gains, with operating cash flow surging by 98.99% 2025 Semi-Annual Key Financial Data | Metric | Current Period (RMB) | Prior Period (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,635,110,083.18 | 2,632,089,783.35 | 0.11% | | Net Profit Attributable to Shareholders of Listed Company | 303,651,052.46 | 253,226,615.60 | 19.91% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | 237,210,048.08 | 179,419,522.02 | 32.21% | | Net Cash Flow from Operating Activities | 286,097,071.23 | 143,774,218.95 | 98.99% | | Basic Earnings Per Share (RMB/share) | 0.25 | 0.21 | 19.05% | | Diluted Earnings Per Share (RMB/share) | 0.25 | 0.21 | 19.05% | | Weighted Average Return on Net Assets | 3.49% | 2.96% | 0.53% | | **Period-end Indicators** | **Current Period-end (RMB)** | **Prior Year-end (RMB)** | **Change from Prior Year-end** | | Total Assets | 12,674,139,895.70 | 12,285,788,088.75 | 3.16% | | Net Assets Attributable to Shareholders of Listed Company | 8,771,392,564.72 | 8,521,867,867.56 | 2.93% | - Operating revenue increased by **0.11%**, primarily due to a significant increase in revenue from innovative and self-developed drugs, partially offset by a decrease in volume and price of some proprietary pharmaceutical products, and reduced revenue from vitamin products and pharmaceutical promotion services[18](index=18&type=chunk) - Net profit attributable to shareholders of the listed company (excluding non-recurring items) increased by **32.21%**, mainly driven by higher gross profit from high-value-added innovative and self-developed drugs, increased foreign exchange gains from financial expenses, and reduced credit impairment losses[18](index=18&type=chunk) - Net cash flow from operating activities increased by **98.99%**, primarily because the increase in cash received from sales of goods and provision of services outpaced the increase in cash paid for purchases of goods and acceptance of services[19](index=19&type=chunk) [Non-recurring Gains and Losses and Amounts](index=9&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to RMB 66,441,004.38, mainly comprising disposal gains/losses of non-current assets, government grants, fair value changes of financial assets/liabilities, and other non-operating income 2025 Semi-Annual Non-recurring Gains and Losses | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Disposal gains/losses of non-current assets | 3,389,221.12 | Primarily net gains from disposal of intangible assets during the reporting period. | | Government grants recognized in current profit/loss (excluding those with continuous impact) | 64,177,846.31 | Primarily government grants received during the reporting period. | | Fair value changes and disposal gains/losses of financial assets and liabilities | 44,413.44 | Due to revaluation of foreign exchange derivatives at period-end and gains from matured time deposits. | | Other non-operating income and expenses | 1,847,214.24 | | | Less: Income tax impact | 2,565,065.42 | | | Impact on minority interests (after tax) | 452,625.31 | | | **Total** | **66,441,004.38** | | - Some government grants recognized in current profit/loss (**RMB 5,145,150.23**) were classified as recurring gains/losses because they are closely related to the company's normal operations, comply with national policies, are enjoyed according to established standards, and have a continuous impact on the company's profit and loss[24](index=24&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides a comprehensive analysis of the company's main business, core competitiveness, financial performance, investment activities, and risk management strategies during the reporting period [Main Business Activities During the Reporting Period](index=10&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company's main business involves R&D, production, sales of pharmaceutical products (biologics, chemical drugs, traditional Chinese medicines), vitamins, and polymer materials, along with drug promotion services; innovative drug sales revenue grew by 169.57%, while vitamin products faced competitive pressure - The company primarily engages in the R&D, production, sales, and promotion services of **pharmaceutical products** (biologics, chemical drugs, traditional Chinese medicines), **vitamins, and polymer materials**, operating within the pharmaceutical manufacturing industry[26](index=26&type=chunk) - The pharmaceutical industry is undergoing deep adjustments and innovation breakthroughs, with traditional generic drugs facing pressure and innovative drugs experiencing explosive growth; in H1 2025, pharmaceutical manufacturing operating revenue decreased by **1.2%** and total profit decreased by **2.8%** year-on-year[28](index=28&type=chunk)[29](index=29&type=chunk) - Vitamin B5 and its precursor products hold a **high global market share** and a leading position, but currently face severe supply-demand imbalance and industry reshuffling[32](index=32&type=chunk)[37](index=37&type=chunk) - The company is one of the few Chinese enterprises to have obtained marketing approval from drug regulatory agencies in China, the U.S., EU, and Brazil for its **innovative biological products**, possessing a global pharmaceutical marketing and promotion network[34](index=34&type=chunk) - In H1 2025, proprietary (including imported) pharmaceutical operating revenue increased by **7.22%** year-on-year, and innovative drug sales revenue grew by **169.57%**, serving as the core driver for a significant increase in non-recurring net profit margin[38](index=38&type=chunk) [Company's Main Business](index=10&type=subsection&id=%EF%BC%88%E4%B8%80%EF%BC%89%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company's main business covers biologics, chemical drugs, traditional Chinese medicines, and vitamin products, with biologics like F-627 (Yilishu®) and recombinant human insulin sold globally, alongside various chemical and traditional Chinese medicines, and leading global sales of Vitamin B5 series products Main Product List | Product Category | Product Name | Sales Region | Indication/Description | | :--- | :--- | :--- | :--- | | Biologic | Epegfilgrastim Injection (F-627) | Global Sales | Reduces incidence of infection in febrile neutropenia caused by chemotherapy | | Biologic | Recombinant Human Insulin Injection | Global Sales | Regulates glucose metabolism, lowers blood sugar | | Chemical Drug | Capecitabine Tablets (Xeloda®) | Domestic Sales | Advanced or metastatic gastric cancer, colorectal cancer, breast cancer | | Chemical Drug | Sodium Hyaluronate Cross-linked with Butanediol Diglycidyl Ether Injection (Yinikang) | Domestic Sales | Knee osteoarthritis | | Traditional Chinese Medicine | Xiao'er Qingqiao Granules | Domestic Sales | Wind-heat tonsillitis, fever, sore throat, etc. | | Vitamin | Vitamin B5 and its precursor | Global Sales | Precursor to Coenzyme A, involved in metabolism, feed/food additive | [Industry Development Stage and Company's Industry Position](index=11&type=subsection&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E7%9A%84%E5%8F%91%E5%B1%95%E9%98%B6%E6%AE%B5%E3%80%81%E5%91%A8%E6%9C%9F%E6%80%A7%E7%89%B9%E7%82%B9%E4%BB%A5%E5%8F%8A%E5%85%AC%E5%8F%B8%E6%89%80%E5%A4%84%E7%9A%84%E8%A1%8C%E4%B8%9A%E5%9C%B0%E4%BD%8D) The pharmaceutical industry is in a phase of deep adjustment and innovation, with significant growth in innovative drugs, while the vitamin sector faces supply-demand imbalances; the company holds a prominent position in biologics, small molecules, traditional Chinese medicines, and synthetic biology, particularly in innovative biologics and internationalization - The pharmaceutical industry has entered a phase of deep adjustment and innovation breakthroughs, with traditional generic drugs facing pressure and innovative drugs experiencing explosive growth; the industry as a whole exhibits weak cyclicality and strong defensive characteristics[28](index=28&type=chunk)[31](index=31&type=chunk) - The vitamin industry faces severe supply-demand imbalance and reshuffling, but the company's **Vitamin B5 products** maintain a leading position in the segmented market[32](index=32&type=chunk) - The company has established a full lifecycle system for macromolecular drugs, from new drug discovery to commercial production, and has successfully launched its first innovative biologic, **Yilishu**, in **34 countries** including China, the U.S., EU, and Brazil[34](index=34&type=chunk)[35](index=35&type=chunk) - In the small molecule (chemical drug) sector, the company focuses on a differentiated product chain of 'small, sharp, and special' products, possesses an internationally aligned high-standard production quality management system, and is one of the few domestic enterprises with an integrated international R&D, production, and sales layout for pharmaceuticals[35](index=35&type=chunk) - The company owns **13 exclusive traditional Chinese medicine products** covered by medical insurance, including Baixuekang (Compound Huangdai Tablets®), an effective drug for treating acute promyelocytic leukemia, which is also listed on the **WHO Model List of Essential Medicines**[36](index=36&type=chunk)[37](index=37&type=chunk) [Key Performance Drivers](index=15&type=subsection&id=%EF%BC%88%E4%B8%89%EF%BC%89%E4%B8%BB%E8%A6%81%E4%B8%9A%E7%BB%A9%E9%A9%B1%E5%8A%A8%E5%9B%A0%E7%B4%A0) In H1 2025, the company's performance growth was primarily driven by a 7.22% increase in proprietary pharmaceutical product revenue, especially a 169.57% surge in innovative drug sales, which boosted high-margin business, while Vitamin B5 series products maintained market leadership despite industry competition - In the pharmaceutical preparation business, proprietary (including imported) pharmaceutical operating revenue increased by **7.22%** year-on-year, and innovative drug sales revenue grew by **169.57%**, serving as the core driver for a significant increase in the company's non-recurring net profit margin[38](index=38&type=chunk) - Although **Vitamin B5 series products** were affected by industry competition, leading to declines in average transaction prices and sales volumes, the company maintained its **market-leading position** through cost reduction, efficiency improvement, and strengthened management[38](index=38&type=chunk) [Analysis of Core Competitiveness](index=15&type=section&id=%E4%BA%8C%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness remained unchanged during the reporting period, with specific details available in the 2024 Annual Report - The company's core competitiveness remained unchanged during the reporting period, as detailed in the **2024 Annual Report**[39](index=39&type=chunk) [Analysis of Main Business](index=15&type=section&id=%E4%B8%89%E3%80%81%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) In H1 2025, the company achieved operating revenue of RMB 2.635 billion, a 0.11% increase, and net profit attributable to shareholders of RMB 304 million, up 19.91%; pharmaceutical-related revenue accounted for 85.53% of total revenue, with innovative drugs Yilishu® and Yinikang® sales growing by 169.57%, alongside significant progress in biologics commercialization, global operations, BD collaborations, high-quality R&D, and synthetic biology new product development 2025 Semi-Annual Key Financial Indicators | Metric | Amount (RMB 10,000) | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 263,511.01 | 0.11% | | Net Profit Attributable to Shareholders of Listed Company | 30,365.11 | 19.91% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | 23,721.00 | 32.21% | - Pharmaceutical-related operating revenue was **RMB 2,253,705,400** (RMB 225,370.54 ten thousand), accounting for **85.53%** of the company's total operating revenue; combined sales revenue of innovative drugs **Yilishu® and Yinikang®** increased by **169.57%** year-on-year[41](index=41&type=chunk) [Advancing Yilishu Commercialization and Biologics Ecosystem Development](index=16&type=subsection&id=1%E3%80%81%E6%8E%A8%E8%BF%9B%E4%BA%BF%E7%AB%8B%E8%88%92%E5%A4%9A%E4%B8%AA%E5%B8%82%E5%9C%BA%E5%95%86%E4%B8%9A%E5%8C%96%E5%8F%8A%E6%9E%84%E5%BB%BA%E7%94%9F%E7%89%A9%E8%8D%AF%E7%94%9F%E6%80%81%E7%B3%BB%E7%BB%9F) Yilishu® has completed its first shipment to the U.S. market and is approved for sale in 34 countries, with the company actively pursuing global commercial collaborations and advancing R&D projects like F-652 and N-3C01, while construction of the Shanghai International Innovation Center and Hefei Xinzhu Gene Recombinant Industrial Base progresses significantly - The first self-developed Class I macromolecular innovative biologic, **Yilishu®**, completed its first shipment to the U.S. market, with a market retail price of **USD 4,600 per dose**, marking its official entry into the U.S. market[42](index=42&type=chunk) - **Yilishu®** has been approved for marketing and sales in **34 countries**, including China, the U.S., EU, and Brazil, with shipments or sales realized in **5 countries**[42](index=42&type=chunk) - The **NMPA approved a supplementary application** for Yilishu® to change from 48-hour to 24-hour administration, the **EU approved self-injection**, and the Japanese partner initiated studies for shorter administration times[43](index=43&type=chunk) - The innovative drug **N-3C01 project** has largely completed preclinical research and will soon submit a clinical application, with potential indications for **bladder cancer and pan-solid tumors**[44](index=44&type=chunk) - The **Shanghai International Innovation Center project** completed civil engineering and outdoor works, the Hefei Xinzhu Gene Recombinant Industrial Base project's formulation line underwent debugging and validation, and the **1000L bulk drug production line** entered the trial production acceptance phase[45](index=45&type=chunk) [Anchoring Overseas Strategy, Consolidating Domestic and International Sales Systems](index=17&type=subsection&id=2%E3%80%81%E9%94%9A%E5%AE%9A%E5%87%BA%E6%B5%B7%E6%88%98%E7%95%A5%EF%BC%8C%E5%90%88%E5%B9%B6%E5%A2%83%E5%86%85%E5%A4%96%E9%94%80%E5%94%AE%E4%BD%93%E7%B3%BB%EF%BC%8C%E4%BB%A5%E5%85%A8%E7%90%83%E4%B8%80%E4%BD%93%E5%8C%96%E8%BF%90%E8%90%A5%E9%A9%B1%E5%8A%A8%E4%B8%9A%E7%BB%A9%E5%A2%9E%E9%95%BF) The company consolidated its domestic and international sales systems into a Global Commercial Business Unit to unify pharmaceutical market operations; overseas pharmaceutical preparation revenue increased by 6.46%, domestic pharmaceutical market revenue grew by 3.57%, and innovative drugs Yilishu® and Yinikang® sales surged by 169.57% - The company merged its domestic and international sales systems, establishing a **Global Commercial Business Unit** to coordinate business development, product marketing, market planning, sales strategies, and operations for both domestic and international pharmaceutical markets[46](index=46&type=chunk) - Overseas pharmaceutical preparations achieved operating revenue of **RMB 331,988,900** (RMB 33,198.89 ten thousand), a year-on-year increase of **6.46%**[47](index=47&type=chunk) - Domestic pharmaceutical market achieved operating revenue of **RMB 1,921,716,500** (RMB 192,171.65 ten thousand), a year-on-year increase of **3.57%**, with proprietary (including imported) pharmaceuticals achieving operating revenue of **RMB 1,768,848,900** (RMB 176,884.89 ten thousand), a year-on-year increase of **7.20%**[48](index=48&type=chunk) - Combined sales revenue of the two innovative drugs, **Yilishu® and Yinikang®**, increased by **169.57%** year-on-year, showing an accelerating volume trend[48](index=48&type=chunk) [Integrating Dispersed Resources, Launching Global BD Center](index=17&type=subsection&id=3%E3%80%81%E6%95%B4%E5%90%88%E5%88%86%E6%95%A3%E8%B5%84%E6%BA%90%EF%BC%8C%E5%8A%A9%E5%8A%9B%E5%85%A8%E7%90%83%20BD%20%E4%B8%AD%E5%BF%83%E5%90%AF%E8%88%AA) The company established a Global BD Center to coordinate product transactions, cross-border negotiations, alliance management, and ecosystem building, strengthening external collaborations; during the reporting period, it signed multiple cooperation agreements in Europe, Malaysia, India, and with Bayer China, and licensed oxytocin nasal spray commercialization in Russia - The company established a **Global BD Center**, responsible for transaction execution and cross-border negotiations, alliance management and ecosystem building, internationalization, and regional market expansion for products across various business units[50](index=50&type=chunk) - On the inbound side, cooperation agreements were signed with **Phar OS (Europe), Novugen (Malaysia), and Mankind (India)**, and an exclusive market promotion right for **Bayer's Xofigo® and Nexavar®** in mainland China was secured with Bayer China[51](index=51&type=chunk) - On the outbound side, a cooperation agreement was signed with **Sygardis Rus, LLC (Russia)**, authorizing them to commercialize oxytocin nasal spray in the Russian market[51](index=51&type=chunk) [Promoting High-Quality R&D and Production, Supporting Company Transformation and Upgrading](index=18&type=subsection&id=4%E3%80%81%E6%8E%A8%E8%BF%9B%E7%A0%94%E4%BA%A7%E9%AB%98%E8%B4%A8%E9%87%8F%E5%8F%91%E5%B1%95%EF%BC%8C%E5%8A%A9%E5%8A%9B%E5%85%AC%E5%8F%B8%E8%BD%AC%E5%9E%8B%E5%8D%87%E7%BA%A7) The small molecule (traditional Chinese medicine) business unit focuses on high-barrier areas like solid tumors, hematologic tumors, and rare diseases, obtaining four chemical drug registration certificates and submitting two formulation product registration applications; progress was made in traditional Chinese medicine new drug research, and internationalization achieved breakthroughs with Amikacin Sulfate Injection shipped to Italy - Domestic pharmaceutical R&D (chemical drugs) obtained **4 product registration certificates**, including Etazocine Hydrobromide Injection, and submitted **2 formulation product registration applications**, including Bilastine Oral Solution[52](index=52&type=chunk) - The statistical report for the Phase Ib patient study of the Class 1.1 traditional Chinese medicine new drug **Duanjin Jiedu Capsule** was completed; enrollment and follow-up for the Phase III clinical trial of Compound Yinhua Jiedu Granules for pediatric influenza were completed[53](index=53&type=chunk)[54](index=54&type=chunk) - The ethics approval for the lead unit of the IIT clinical study of **Compound Huangdai Tablets** for treating advanced recurrent platinum-resistant ovarian cancer patients was obtained, marking a crucial step towards treating ovarian cancer[54](index=54&type=chunk) - Breakthrough progress was made in internationalization, with **Amikacin Sulfate Injection** successfully shipped to the Italian market, and **Norepinephrine Bitartrate Injection** completing its PIC/S certification on-site inspection[55](index=55&type=chunk) [Synthetic Biology Sector: Significant Progress in New Product R&D and Construction, B5 Series Products Maintain Leading Edge](index=19&type=subsection&id=5%E3%80%81%E5%90%88%E6%88%90%E7%94%9F%E7%89%A9%E6%9D%BF%E5%9D%97%EF%BC%8C%E6%96%B0%E4%BA%A7%E5%93%81%E7%A0%94%E5%8F%91%E5%BB%BA%E8%AE%BE%E8%BF%9B%E5%B1%95%E6%98%BE%E8%91%97%EF%BC%8CB5%20%E7%B3%BB%E5%88%97%E4%BA%A7%E5%93%81%E7%BB%A7%E7%BB%AD%E4%BF%9D%E6%8C%81%E9%A2%86%E5%85%88%E4%BC%98%E5%8A%BF) The synthetic biology business unit increased investment in new product development, with Human Milk Oligosaccharide (HMO) 2'-FL obtaining FDA GRAS certification and 6'-SL obtaining Self-GRAS certification; Vitamin B5 series products maintained market leadership despite industry competition, and construction of the Hangzhou Synthetic Biology Industrial Park Phase I is accelerating - Human Milk Oligosaccharide (HMO) **2'-FL obtained FDA GRAS safety certification**, and **6'-SL obtained Self-GRAS certification**, with registration efforts in other regions progressing concurrently[56](index=56&type=chunk) - Although **Vitamin B5 series products** were affected by industry competition, leading to declines in average transaction prices and sales volumes, they still maintained a **market-leading position**[56](index=56&type=chunk) - Construction and equipment installation for the four buildings of the **Hangzhou Synthetic Biology Industrial Park Phase I project** are accelerating[56](index=56&type=chunk) Operating Revenue Composition (by Industry) | Industry | Current Period Amount (RMB) | Share of Operating Revenue | Prior Period Amount (RMB) | Share of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Pharmaceutical | 2,253,705,361.70 | 85.53% | 2,167,257,866.51 | 82.34% | 3.99% | | Vitamin | 302,225,793.57 | 11.47% | 375,941,164.06 | 14.28% | -19.61% | | Polymer Materials | 79,178,927.91 | 3.00% | 88,890,752.78 | 3.38% | -10.93% | Operating Revenue Composition (by Product) | Product | Current Period Amount (RMB) | Share of Operating Revenue | Prior Period Amount (RMB) | Share of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Proprietary Pharmaceutical Products (incl. imported) | 1,990,001,955.45 | 75.52% | 1,856,050,098.60 | 70.52% | 7.22% | | Other Pharmaceutical Products | 250,904,572.83 | 9.52% | 242,788,226.46 | 9.22% | 3.34% | | Pharmaceutical Services | 12,798,833.42 | 0.49% | 68,419,541.45 | 2.60% | -81.29% | | Vitamin | 302,225,793.57 | 11.47% | 375,941,164.06 | 14.28% | -19.61% | | Polymer Materials | 79,178,927.91 | 3.00% | 88,890,752.78 | 3.38% | -10.93% | Operating Revenue Composition (by Region) | Region | Current Period Amount (RMB) | Share of Operating Revenue | Prior Period Amount (RMB) | Share of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Domestic | 2,075,408,442.12 | 78.76% | 2,025,625,964.71 | 76.96% | 2.46% | | Overseas | 559,701,641.06 | 21.24% | 606,463,818.64 | 23.04% | -7.71% | [Analysis of Non-Core Business](index=21&type=section&id=%E5%9B%9B%E3%80%81%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) The company's non-core business impacted total profit, primarily through investment income (associate losses), fair value changes (foreign exchange derivatives revaluation), asset impairment (inventories and intangible assets), non-operating income (litigation compensation), non-operating expenses (fixed asset disposals), and credit impairment (receivables bad debt provisions), none of which are sustainable Impact of Non-Core Business on Total Profit | Item | Amount (RMB) | Share of Total Profit | Reason for Formation | Sustainable | | :--- | :--- | :--- | :--- | :--- | | Investment Income | -14,370,446.64 | -4.17% | Primarily investment losses recognized from associate losses during the reporting period. | No | | Fair Value Change Gains/Losses | -459,827.92 | -0.13% | Due to revaluation of foreign exchange derivatives at period-end. | No | | Asset Impairment | -11,333,286.25 | -3.29% | Due to impairment losses on inventories and intangible assets recognized during the reporting period. | No | | Non-Operating Income | 2,571,952.61 | 0.75% | Primarily litigation compensation received during the reporting period. | No | | Non-Operating Expenses | 1,193,751.91 | 0.35% | Primarily losses from fixed asset disposals and compensation payments during the reporting period. | No | | Credit Impairment | -23,146,737.30 | -6.72% | Primarily bad debt provisions for receivables recognized based on aging portfolio during the reporting period. | No | | Other Income | 69,741,135.46 | 20.25% | Primarily income-related government grants received during the reporting period. | No | | Asset Disposal Gains | 3,858,234.66 | 1.12% | Primarily net gains from disposal of intangible assets during the reporting period. | No | [Analysis of Assets and Liabilities](index=21&type=section&id=%E4%BA%94%E3%80%81%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) At period-end, total assets were RMB 12.674 billion, up 3.16% from year-end, with construction in progress significantly increasing by 2.43% due to investments in industrial parks and innovation centers; long-term borrowings increased by 0.80%, while non-current liabilities due within one year decreased by 1.48%, and overseas assets constituted 45.67% of net assets Significant Changes in Asset Composition | Item | Current Period-end Amount (RMB) | Share of Total Assets | Prior Year-end Amount (RMB) | Share of Total Assets | Change in Share | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Total Assets | 12,674,139,895.70 | 100% | 12,285,788,088.75 | 100% | 3.16% | | | Construction in Progress | 1,140,989,321.45 | 9.00% | 807,153,241.00 | 6.57% | 2.43% | Due to increased investment in the Vitamin Industrial Park, Gene Recombinant Biopharmaceutical Base Project, and International Innovation Center Project during the reporting period. | | Long-term Borrowings | 747,170,028.46 | 5.90% | 627,163,153.57 | 5.10% | 0.80% | Primarily due to changes in loan structure, new project borrowings, and reclassification to non-current liabilities due within one year during the reporting period. | | Non-current Liabilities Due Within One Year | 389,190,380.76 | 3.07% | 558,892,484.59 | 4.55% | -1.48% | Primarily due to reduced reclassification of long-term borrowings to non-current liabilities due within one year during the reporting period. | - Total overseas assets amounted to **RMB 5,745,898,863.19**, accounting for **45.67%** of the company's net assets, primarily including assets of subsidiaries such as Hong Kong Yifan, Yifan International, and Yiyi Bio[69](index=69&type=chunk) - The company's financial assets measured at fair value totaled **RMB 85,371,843.49** at period-end, mainly comprising other debt investments and other equity instrument investments; financial liabilities totaled **RMB 459,827.92** at period-end, primarily trading financial liabilities (revaluation of foreign exchange derivatives)[71](index=71&type=chunk) [Analysis of Investment Status](index=23&type=section

证券代码：002019 证券简称：亿帆医药 公告编号：2025-044 亿帆医药股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《2025年半年度报告摘要》及《2025年半年度报告》。 （二）会议以8票同意、0票反对、0票弃权的结果，审议通过了《关于修订 <公司章程>的议案》 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《< 公司章程>修正案（2025 年 8 月修订）》及全文。 （三）审议通过了《关于董事会换届选举非独立董事的议案》 鉴于公司第八届董事会董事任期已届满，根据《公司法》《公司章程》和《董 事会议事规则》等有关规定，并经公司董事会提名委员会审核，公司第八届董事 会同意提名程先锋先生、林行先生、冯德崎先生为公司第九届董事会非独立董事 候选人。表决情况如下： 3.1、提名程先锋先生为公司第九届董事会非独立董事候选人； 表决结果：8 票同意、0 ...

亿帆医药公告，2025年上半年营业收入26.35亿元，同比增长0.11%。净利润3.04亿元，同比增长 19.91%。 ...

Group 1 - Multiple listed companies have proposed share buybacks to bolster market confidence [1][2][3] - Yifan Pharmaceutical plans to repurchase shares at a price not exceeding 20.57 CNY per share, with a total buyback amount between 30 million CNY and 50 million CNY [1] - Ruilian New Materials intends to buy back shares with a total amount between 50 million CNY and 80 million CNY, at a price not exceeding 51 CNY per share [1] - Kairda plans to repurchase shares with a total amount between 50 million CNY and 60 million CNY, with a price cap based on the average trading price [2] - Sike Rui proposes a buyback with a total amount between 30 million CNY and 50 million CNY, at a price not exceeding 80 CNY per share [2] - Longxin Zhongke also plans a buyback with a total amount between 30 million CNY and 50 million CNY, at a price not exceeding 128 CNY per share [2] Group 2 - Biyi Micro plans to repurchase shares with a total amount between 42 million CNY and 84 million CNY, at a price not exceeding 78 CNY per share [3] - Dongjian Technology's major shareholder plans to increase holdings between 10 million CNY and 20 million CNY without a price range [3] - Bangjie shares have adjusted their planned increase in holdings from 30 million CNY to 60 million CNY to a new range of 35 million CNY to 70 million CNY [3] Group 3 - The effectiveness of these buyback and increase plans in attracting investor interest remains uncertain, as seen with Dongjian Technology's recent share reduction plans [4] - Dongjian Technology's shareholders have previously reduced their holdings by 6.15 million shares, representing 1.46% of total shares, and have announced new reduction plans [4]

Core Insights - The article highlights the recent achievements of Chinese pharmaceutical companies, particularly Heng Rui Medicine and Fosun Pharma, in obtaining Fast Track Designation (FTD) from the FDA for their innovative drugs, indicating a significant step in the internationalization of Chinese pharmaceuticals [1][2]. Group 1: Fast Track Designation - Heng Rui Medicine's SHR-A2009 is the first innovative drug from the company to receive FDA's Fast Track Designation, which is expected to expedite its clinical trials and market registration [2]. - Fosun Pharma's subsidiary, Hanhui, also received FTD for HLX42, a drug targeting advanced non-small cell lung cancer, with a cumulative R&D investment of approximately 6.285 million yuan [2]. - The FTD status allows for increased communication with the FDA during the drug development process, facilitating quicker identification and resolution of issues [3]. Group 2: ADC Market Growth - Both SHR-A2009 and HLX42 are part of the Antibody-Drug Conjugate (ADC) sector, which has seen a surge in interest and investment from Chinese companies [4]. - As of December 2023, over 20 ADC transactions have occurred, with a total value exceeding 35 billion USD, indicating a robust market for these innovative therapies [4]. - The global ADC market is projected to grow from 11.4 billion USD in 2023 to 64.7 billion USD by 2030, with a compound annual growth rate (CAGR) of 28.1% [4]. Group 3: International Expansion of Chinese Pharma - 2023 is marked as a breakthrough year for Chinese innovative drugs entering international markets, with several companies achieving FDA approvals [6]. - Chinese pharmaceutical companies are encouraged to develop competitive products to capture overseas market share while also focusing on domestic and international sales strategies [6]. - The recognition of Chinese innovation in the global pharmaceutical ecosystem is increasing, as evidenced by successful licensing agreements for various innovative therapies [6].

Core Viewpoint - The company YiFan Pharmaceutical is engaged in ongoing discussions regarding its research project F-652, particularly in relation to its collaboration with a funding agency for further clinical development in the U.S. [1] Group 1: Company Developments - YiFan Pharmaceutical received a question from an investor about the recent licensing agreement between Hengrui and GSK, which included an upfront payment of $500 million and potential future payments totaling up to $12 billion [1] - The company confirmed that the research project F-652, targeting alcoholic liver disease, will prioritize collaboration with the funding agency for subsequent research in the U.S. [1] - The decision on further discussions regarding business development (BD) will be made after obtaining relevant clinical data [1]

Investment Rating - The report maintains a strong investment rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [7]. Core Insights - The report highlights the recent policy push for brain-computer interface (BCI) technology, emphasizing the potential for a trillion-dollar market opportunity. The government aims to cultivate 2-3 global leading companies in this field by 2030, showcasing the urgency to position within this emerging industry [4][16][17]. Market Review - The CITIC Pharmaceutical Index fell by 0.8% during the week of August 4-8, 2025, underperforming the CSI 300 Index by 2.0 percentage points. However, since the beginning of 2025, the CITIC Pharmaceutical and Biotechnology Index has risen by 21.8%, outperforming the CSI 300 Index by 17.5 percentage points [3][31]. - The top five performing stocks during this week included Nanmo Biology (+42.5%), Haichen Pharmaceutical (+41.3%), Sainuo Medical (+39.5%), Chengyi Pharmaceutical (+35.8%), and Dabo Medical (+31.5%) [3][48]. Investment Focus - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as medical devices, which are expected to see a policy turning point. The report encourages identifying high-performing stocks as companies begin to disclose mid-year results [5][16]. - Specific companies to watch include Mailland, Xiangyu Medical, Chengyitong, Innovation Medical, and Sanbo Brain Science, which are positioned well within the BCI sector [4][16][17]. Policy Developments - Recent policies from seven ministries, including the Ministry of Industry and Information Technology, outline a clear development roadmap for BCI technology, covering aspects from technical breakthroughs to global competitiveness [4][18][22]. - By 2027, key technological breakthroughs are expected, with the establishment of an advanced technical and industrial system. The BCI market is projected to grow significantly, with the global medical BCI market expected to reach $40 billion by 2030 and $145 billion by 2040 [22][23]. Company Developments - Notable companies in the BCI space include: - **Qiangnao Technology**: Focused on non-invasive BCI, received FDA approval for its smart bionic hand. - **Nerve Tiger Technology**: Achieved real-time motion decoding and language understanding with its invasive BCI technology. - **Mikron Medical**: Developing a range of non-invasive BCI products and collaborating with hospitals for research [29][30]. This summary encapsulates the key points from the industry report, focusing on investment opportunities, market performance, and policy developments within the pharmaceutical and biotechnology sectors, particularly in relation to brain-computer interfaces.

Core Insights - Yifan Pharmaceutical (002019) reported a closing price of 14.69 yuan as of August 8, 2025, reflecting a decline of 1.67% [1] - The company experienced a net outflow of main funds amounting to 57.17 million yuan, which accounted for 19.13% of the total transaction amount [1] - The latest quarterly report indicated total revenue of 1.327 billion yuan, a year-on-year growth of 0.05%, and a net profit attributable to shareholders of 153 million yuan, up 4.83% year-on-year [1] Financial Performance - The company's total revenue for Q1 2025 was 1.327 billion yuan, with a slight increase of 0.05% compared to the previous year [1] - Net profit attributable to shareholders reached 153 million yuan, representing a year-on-year increase of 4.83% [1] - The company's non-recurring net profit was 95.37 million yuan, showing a decrease of 13.55% year-on-year [1] - Key financial ratios include a current ratio of 1.370, a quick ratio of 0.984, and a debt-to-asset ratio of 31.36% [1] Company Overview - Yifan Pharmaceutical Co., Ltd. was established in 2000 and is located in Hangzhou, primarily engaged in research and experimental development [1] - The company has a registered capital of 12.1639 billion yuan, which is also its paid-in capital [1] - The legal representative of the company is Cheng Xianfeng [1] Investment and Intellectual Property - Yifan Pharmaceutical has made investments in 18 external companies and participated in 5 bidding projects [2] - The company holds 23 trademark registrations and 11 patents, along with 12 administrative licenses [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 1.80% from July 25, 2025, to August 7, 2025, exceeding the CSI 300 index by approximately 2.62 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and chemical preparation sectors leading with increases of 6.32% and 4.33%, respectively [13]. - Approximately 61% of stocks in the industry achieved positive returns, with notable performers such as Lide Man, which saw a weekly increase of 71.70% [14][17]. - The overall industry valuation remains stable, with a PE (TTM) of approximately 52.61 times as of August 7, 2025, which is relatively low compared to historical levels [18]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 1.80% from July 25, 2025, to August 7, 2025, surpassing the CSI 300 by about 2.62 percentage points [12]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and chemical preparations, which increased by 6.32% and 4.33%, while hospitals and vaccines saw declines of 1.88% and 1.76% [13]. - About 61% of stocks in the industry posted positive returns, with Lide Man leading at a 71.70% increase [14][17]. 2. Industry News - The 11th batch of national drug procurement officially began reporting on August 6, 2025, with key deadlines for data submission and review set for August 25 and August 27, respectively [24]. 3. Company Announcements - Yifan Pharmaceutical announced that its subsidiary received a drug registration acceptance notice for melatonin granules, marking a significant milestone as the first domestic application for this product [25]. 4. Weekly Industry Perspective - The report maintains an "Overweight" rating for the industry, highlighting the continuous outperformance of the pharmaceutical and biotechnology sector against the CSI 300 index, driven by new business development (BD) authorizations and positive earnings forecasts from medical research outsourcing companies [26][28].

Group 1: Industry Overview - The Chinese innovative drug sector has experienced significant growth, with the innovative drug index rising by 49.74% year-to-date as of August 7, 2025, outperforming the broader market [1] - The sector is witnessing an increase in research and development achievements, large business development (BD) transactions, and a faster pace of international expansion among biopharmaceutical companies [1] - The Shenzhen Stock Exchange has introduced a third set of listing standards to support high-quality, unprofitable companies in the biopharmaceutical and medical device sectors, enhancing market inclusivity [1] Group 2: Internationalization of Chinese Drug Companies - In the first half of 2025, the overseas BD transaction amount for Chinese pharmaceutical companies reached $60 billion, surpassing the total for 2024, reflecting improved R&D efficiency and cost advantages [2] - Companies like Betta Pharmaceuticals are pushing for internationalization, with their product, Ensartinib, receiving FDA approval in 2024, marking a significant step in their global commercial capabilities [2] - The proportion of Chinese companies in overseas licensing deals with upfront payments exceeding $50 million has increased from 4% five years ago to 42% currently, indicating a shift in global pharmaceutical dynamics [2] Group 3: Market Recognition and Support - Global markets are increasingly recognizing the innovation of Chinese enterprises, supported by favorable domestic policies and market conditions [3] - The collaboration between local companies and multinational pharmaceutical firms is raising the industry's ceiling, enhancing corporate value and market perception [3] - Companies are advised to leverage their strengths and consider various internationalization strategies, including licensing, mergers, and acquisitions [3] Group 4: Financing and Capital Market Support - The capital market plays a crucial role in supporting the long and costly R&D cycles of innovative drugs, with the Shenzhen Stock Exchange providing lifecycle services through IPOs and mergers [5] - Companies are diversifying their financing tools, with examples of successful fundraising leading to significant market valuations, such as Kelun Pharmaceutical's subsidiary surpassing a market cap of 100 billion [5] - There are calls for regulatory support to allow phased financing for early-stage innovations, as current restrictions pose challenges for fundraising [5] Group 5: Support for Startups and Early-Stage Companies - Startups in the innovative drug sector require financial backing, with recent developments allowing for knowledge property pledges and government risk compensation loans [6] - Local government-backed funds are emerging as key players in providing patient capital to support the growth of innovative drug companies [6] - Investment institutions are encouraged to provide comprehensive support to companies, from early identification of research achievements to ongoing assistance in commercialization [6]